ICON Appoints Dr. Steve Cutler as Chief Operating Officer
09 Janeiro 2014 - 12:30PM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of outsourced
development services to the pharmaceutical, biotechnology and
medical device industries, today announced that Dr. Steve Cutler
has been appointed to the newly created position of Chief Operating
Officer (COO), ICON plc.
Dr. Cutler joined ICON in November 2011 as Group President,
Clinical Research Services. In his new role as COO, Dr. Cutler has
responsibility for all of ICON’s operational units, covering Early
Phase, Clinical, Laboratories, Commercialisation and Outcomes and
DOCS FSP & resourcing. Dr Cutler will also take responsibility
for ICON’s sales and marketing and strategic alliance teams.
Within Dr. Cutler’s team, Dr. Nuala Murphy has been appointed
President, ICON Clinical Services and Mr. Jim Miskel has been
appointed Executive Vice President & General Manager, ICON
Laboratory Services.
Dr. Murphy joined ICON in 2012 as Executive Vice President,
Global Clinical Operations and Data Management, bringing to ICON
over 22 years’ experience within the pharmaceutical and CRO
industries. In her new role, Dr. Murphy will oversee ICON’s global
clinical services, comprising clinical and data operations, study
start-up, project management, clinical risk management, technology
services and clinical scientific operations.
Mr. Miskel joined ICON in November 2013 and will lead ICON’s
newly combined Central and Bioanalytical laboratories group. He
brings a wealth of laboratory and pharmaceutical industry
experience to ICON, having previously held senior positions with
Harlan Laboratories, MDS Pharma Services, Wyeth Pharmaceuticals and
McKinsey & Company.
Commenting on the appointments, Ciaran Murray, Chief Executive
Officer, ICON plc, said: “We continually review our structure to
ensure that as the market evolves, our organisation can continue to
provide customers with innovative and integrated solutions across
our various service lines and business units. Bringing all
operational units under Steve’s leadership will allow us to further
enhance the support we can offer to our customers’ development
programs. I would like to congratulate Steve, Nuala and Jim on
their new roles and wish them every success in the future.”
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has approximately 10,300 employees, operating from 77 locations in
38 countries.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
ICON Media ContactGenevieve TuckWeber ShandwickTel: +44
(0)20 7067 0655gtuck@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024